Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion BCGC-1 of zongertinib alone or in combinations for HER2-positive metastatic breast and upper gastrointestinal cancers
jRCT2031240135Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of zongertinib in breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of dose-limiting toxicities in the maximum tolerated dose evaluation period and Objective response. Started Aug 2024; status: recruiting.
02
Drugs
zongertinib
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031240135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240135.